Vittoria Biotherapeutics

Homepage

Philadelphia, United States · Founded 2021 · $10.0M raised

Employees
1–10
Founded
2021
Business Model
B2B
Total Funding
$10.0M
Last Round
$10.0M Extension RoundNov 2024
Rounds
2

About

viTToria Biotherapeutics is a clinical-stage biotherapeutics company spun out of Penn Medicine in 2021, founded by Dr. Marco Ruella to develop next-generation CAR T-cell immunotherapies for cancer and autoimmune diseases. The company's proprietary SENZA5 platform technology achieves superior potency through CD5 signaling modulation and a novel 5-day manufacturing process, enabling autologous cell therapies that improve on the efficacy, safety, and accessibility of current CAR T treatments. Vittoria's lead program, VIPER-101, is in Phase 1 clinical trials targeting T-cell lymphoma, a malignancy for which existing treatment options remain severely limited.

Summary

Vittoria Biotherapeutics is a Biotech company based in Philadelphia, United States, founded in 2021. It has raised $10.0M in total across 2 rounds, most recently a $10.0M Extension Round round in Nov 2024.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundNov 2024
$10.0M

Sign up to see all 2 rounds

Private Equity through Extension Round — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Vittoria Biotherapeutics on Indexed.vc
<a href="https://indexed.vc/companies/vittoria-biotherapeutics"><img src="https://indexed.vc/api/badge/company/vittoria-biotherapeutics" alt="Vittoria Biotherapeutics on Indexed.vc" width="260" height="76" /></a>